

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	226807	HIV fusion	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:44
L2	940	anti adj trypsin	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:45
L3	7747	antitrypsin	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:45
L4	8326	L2 or L3	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:46
L5	4639	L4 and (alpha near3 antitrypsin)	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:46
L6	915	L4 and (alpha near4 trypsin)	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:48
L7	65	L4 and (AAT near3 sequence)	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:48

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	226807	HIV fusion	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:44
L2	940	anti adj trypsin	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:45
L3	7747	antitrypsin	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:45
L4	8326	L2 or L3	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:46
L5	4639	L4 and (alpha near3 antitrypsin)	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:46
L6	915	L4 and (alpha near4 trypsin)	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:48
L7	65	L4 and (AAT near3 sequence)	US-PGPUB; USPAT; USOCR	OR	ON	2007/02/23 11:48

US 20070003943 A1	US-PGPUB	US 5714345 A	USPAT
US 20060269536 A1	US-PGPUB	US 5668107 A	USPAT
US 20060246074 A1	US-PGPUB	US 5650503 A	USPAT
US 20060057117 A1	US-PGPUB	US 5648254 A	USPAT
US 20060040867 A1	US-PGPUB	US 5622930 A	USPAT
US 20050277106 A1	US-PGPUB	US 5525494 A	USPAT
US 20050232921 A1	US-PGPUB	US 5439824 A	USPAT
US 20050201951 A1	US-PGPUB	US 5420110 A	USPAT
US 20050192429 A1	US-PGPUB	US 5412073 A	USPAT
US 20050181979 A1	US-PGPUB	US 4937324 A	USPAT
US 20050137156 A1	US-PGPUB		
US 20050137153 A1	US-PGPUB		
US 20050124010 A1	US-PGPUB		
US 20050084972 A1	US-PGPUB		
US 20050059117 A1	US-PGPUB		
US 20050026838 A1	US-PGPUB		
US 20040175383 A1	US-PGPUB		
US 20040143103 A1	US-PGPUB		
US 20040142416 A1	US-PGPUB		
US 20040077090 A1	US-PGPUB		
US 20030215921 A1	US-PGPUB		
US 20030176674 A1	US-PGPUB		
US 20030175274 A1	US-PGPUB		
US 20030170786 A1	US-PGPUB		
US 20030138784 A1	US-PGPUB		
US 20030113388 A1	US-PGPUB		
US 20030073217 A1	US-PGPUB		
US 20030053998 A1	US-PGPUB		
US 20030033634 A1	US-PGPUB		
US 20030028007 A1	US-PGPUB		
US 20020164695 A1	US-PGPUB		
US 20020160402 A1	US-PGPUB		
US 20020155508 A1	US-PGPUB		
US 20020150940 A1	US-PGPUB		
US 20020146733 A1	US-PGPUB		
US 20020131961 A1	US-PGPUB		
US 20020120953 A1	US-PGPUB		
US 20020082224 A1	US-PGPUB		
US 7049098 B2	USPAT		
US 7045354 B2	USPAT		
US 7033781 B1	USPAT		
US 7018833 B2	USPAT		
US 6924267 B2	USPAT		
US 6919493 B2	USPAT		
US 6900018 B2	USPAT		
US 6734285 B2	USPAT		
US 6680425 B1	USPAT		
US 6548735 B1	USPAT		
US 6410241 B1	USPAT		
US 6127145 A	USPAT		
US 6083902 A	USPAT		
US 6066781 A	USPAT		
US 6048973 A	USPAT		
US 5861299 A	USPAT		
US 5736379 A	USPAT		

**ANDERMANN 10/ 539 627 = anti-HIV peptides approx. 20-mers**

LOGINID:SSPTAHPY1654

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:21:54 ON 23 FEB 2007

=> file registry

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s LEAIPM/sqsp

L1 291 LEAIPM/SQSP

=> file CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

30.70

30.91

FILE 'CAPLUS' ENTERED AT 12:23:47 ON 23 FEB 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 23 Feb 2007 VOL 146 ISS 10

FILE LAST UPDATED: 22 Feb 2007 (20070222/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s L1 and PATENT/dt

143 L1

5614010 PATENT/DT

L2

114 L1 AND PATENT/DT

=> dup rem L2

PROCESSING COMPLETED FOR L2

L3

112 DUP REM L2 (2 DUPLICATES REMOVED)

=> d L3 1-12 bib abs

L3 ANSWER 1 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:53944 CAPLUS

DN 146:178407

TI Predicting sites for hydroxyproline glycosylation in secreted plant proteins and their use in developing secretory expression systems

IN Kieliszewski, Marcia J.; Xu, Jianfeng

PA Ohio University, USA  
SO PCT Int. Appl., 112pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007008708	A2	20070118	WO 2006-US26594	20060710
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, -FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-697337P P 20050708

AB Proteins glycosylated at hydroxyproline residues are more likely to be efficiently secreted from plant cells than are protein without these modifications. Methods for the prediction of sites for proline hydroxylation and hydroxyproline glycosylation in proteins are described. These methods include a series of tests in which the protein sequence is checked by sets of rules with the passing or failing of the test sending it to new tests. Such methods can be used to identify non-plant proteins that have the motifs assocd. with these processes and so likely to become glycosylated in plant cells, and to identify sites in non-plant proteins that can be converted into hydroxyproline glycosylation sites to increase the efficiency of secretion. It is also possible to det. empirically whether a particular protein will undergo hydroxyproline glycosylation suitable for the desired level of secretion in plant cells.

L3 ANSWER 2 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2007:38162 CAPLUS

DN 146:135565

TI Compositions containing neutral lipids and lung surfactant proteins for treatment of respiratory diseases

IN Chochrane, Charles G.

PA The Scripps Research Institute, USA

SO PCT Int. Appl., 94pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007005672	A2	20070111	WO 2006-US25705	20060630
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-695830P P 20050630

AB The invention provides compns. and methods for treating respiratory diseases and conditions. Such compns. and methods utilize a neutral lipid combined with a lung surfactant polypeptide. Thus, a model compn. contains (KLLLL)4K, 1,2-dipalmitoylphosphatidylcholine, 1-palmitoyl-2-oleoyl phosphatidylglycerol, cholesterol, and palmitic acid in an aq. buffer.

L3 ANSWER 3 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1312194 CAPLUS

DN 146:55493

TI Methods for reducing graft rejection and promotion of graft survival using compositions comprising serine protease inhibitors, such as .alpha.1-anti-trypsin

IN Shapiro, Leland; Lewis, Eli C.; Dinarello, Charles A.

PA The Regents of the University of Colorado, USA

SO PCT Int. Appl., 81pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006133403	A2	20061214	WO 2006-US22436	20060607
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2005-687850P P 20050607

AB The invention provides methods for reducing the risk of a transplant rejection, such as graft rejection, or side-effects thereof, which involve administration of serine protease inhibitor, such as .alpha.1-anti-trypsin, in combination with anti-transplant agents. The invention also provides methods for treating a subject in need of immunotolerance therapy and/or for preserving an explanted organ or non-organ, which involve administration of a compd. with .alpha.1-anti-trypsin-like activity or a compd. with serine protease inhibiting activity. The invention relates that immunotolerance therapy is selected from group consisting of reducers of apoptosis prodn., reducers of cytokine prodn., reducers of nitric oxide prodn. and a combination thereof.

L3 ANSWER 4 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1252610 CAPLUS

DN 146:23034

TI Biomarkers for breast cancer

IN Li, Jinong; Sukumar, Saraswati; Chan, Daniel W.

PA The Johns Hopkins University, USA

SO PCT Int. Appl., 63pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006128082	A2	20061130	WO 2006-US20643	20060525

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-685459P P 20050526

AB The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying breast cancer status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as breast cancer or non-breast cancer. The biomarkers can be detected by SELDI mass spectrometry.

L3 ANSWER 5 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:888486 CAPLUS

DN 145:299200

TI Cloning and application of proteinase inhibitor genes in transgenic mouse for serpin-related antiinflammation study

IN Ashton-Rickardt, Philip G.; Zhang, Manling

PA University of Chicago, USA

SO PCT Int. Appl., 243pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006091773	A2	20060831	WO 2006-US6524	20060224
	WO 2006091773	A3	20061221		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-656492P P 20050225

AB Disclosed are compns. and methods related to serpins and their function as well as methods related to mechanisms dependent on the serpins. Proteinase inhibitor genes Spi6 and PI9 were cloned and transgenic mice were prepd. for serpin-related antiinflammation study.

L3 ANSWER 6 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:888497 CAPLUS

DN 145:287515

TI Design of recombinant protein inhibitors of human kallikrein 14 containing reactive serpin loop, and use for treatment of proteolysis-related disorders.

IN Deperthes, David; Kuendig, Christoph; Cloutier, Sylvain; Felber, Loyse

PA Universite De Lausanne, Switz.

SO PCT Int. Appl., 101pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006090282	A2	20060831	WO 2006-IB574	20060228
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI WO 2005-IB504 A 20050228

AB The present invention relates to a recombinant inhibitor protein of an hK14 protease (human kallikrein 14) comprising a Reactive Serpin Loop of a serpin sequence which is modified by at least one substrate active site sequence specific for said hK14 protease. Other objects of the invention are to provide a purified and isolated nucleic acid sequence encoding the recombinant inhibitor protein of said hK14 protease, an expression vector comprising said purified and isolated nucleic acid sequence, a eukaryotic or prokaryotic host cell transformed with this expression vector and a method of producing a recombinant inhibitor protein of an hK14 protease. The hK14 inhibitor of the invention can be used for treatment of a proteolysis-related disorder, such as: cancer, inflammation, infection or autoimmune disorder. The nucleotide sequences and the encoded amino acid sequences of hK14 inhibitor proteins based on .alpha.1-antichymotrypsin and .alpha.1-antitrypsin are provided.

L3 ANSWER 7 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:771285 CAPLUS

DN 145:204044

TI Leader sequences for directing secretion and production of polypeptides

IN Halenbeck, Robert Forgan; Bosch, Elizabeth; Linnemann, Thomas; Lee, Ernestine

PA Five Prime Therapeutics, Inc., USA

SO PCT Int. Appl., 86pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 19

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006081430	A2	20060803	WO 2006-US2951	20060127
	WO 2006081430	A9	20061130		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2005-647013P P 20050127



AB The present invention provides nucleic acid and polypeptide constructs for producing proteins in higher yields than when such proteins are produced from sequences that comprise their endogenous signal peptide. Higher yields are achieved either by replacing the endogenous secretory leader sequence with an heterologous secretory sequence, or by adding a heterologous secretory leader sequence to a protein that would otherwise not contain a leader sequence. Accordingly, polypeptide and polynucleotide constructs are provided where the polypeptides and polynucleotides are modified so as to form a fusion mol. with a fusion partner. Leader sequences that are useful for the prodn. of heterologous secretable polypeptides, heterologous secreted polypeptides, nucleic acid constructs that encode such leader sequences and heterologous secreted polynucleotides, vectors and recombinant host cells that contain such nucleic acid constructs, and methods of making and using such secreted polypeptides with such heterologous leader sequences are provided.

L3 ANSWER 8 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:735861 CAPLUS

DN 145:195556

TI Use of tubercidin or SSM/SSMA for treatment of viral infections

IN Katz, Harvey; King, Colm J.; Shapiro, Leland

PA Hard To Treat Diseases, Inc., USA; The Regents of the University of Colorado

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006078369	A2	20060727	WO 2005-US44834	20051212
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2004-636091P P 20041216

AB A novel method of treating and preventing viral diseases is provided. In particular, the present invention relates to compns. and methods for inhibition of viral infections and the diseases assocd. with such viral infections. More particularly, the present invention relates to the inhibitory compds. comprising naturally occurring and man-made compns. comprising a substance exhibiting Tubercin and/or SSM activity or a functional deriv. thereof. Thus, tubercidin and SSMA inhibited IL-18-induced HIV-1 prodn. by U1 cells in a dose-dependent manner. Neither tubercidin nor SSMA were toxic to the U1 cells. Tubercidin also inhibited HIV-1 prodn. in infected PBMC. The earliest stages of HIV-1 infection was inhibited by tubercidin in an in vitro model of HIV-1 infection.

L3 ANSWER 9 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:236707 CAPLUS

DN 144:267306

TI Using .alpha.1-antitrypsin as biomarkers and therapeutic targets for cognitive decline

IN Schmechel, Donald E.; Browndyke, Jeffery N.; Welsh-Bohmer, Kathleen A.;

Sansing-Edwards, Kathy L.  
PA Duke University, USA  
SO PCT Int. Appl., 89 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006028586	A2	20060316	WO 2005-US26180	20050722
	WO 2006028586	A3	20060713		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRAI US 2004-589795P P 20040722

AB The present invention relates to a method for predicting rate of progression of central nervous system diseases by detg. types of alleles of .alpha.1-antitrypsin (AAT) or AAT level in the subject, using the detd. types of alleles or AAT level as a factor to predict rate of progression of cognitive and/or behavioral decline in the subject. Enrichment of S and Z polymorphisms of AAT in distinct subsets of patients with cognitive disorder (pre-existing affective disorders and APOE2 allele carriers) suggests that AAT variants are potential endophenotypes for Alzheimer Disease and related disorders of cognition, behavior and affect. Such disorders include ADD/ADHD, learning disabilities, ADEM, and susceptibility to brain injury in toxic/chem./biol./immunol. events. In Alzheimer Disease, S and Z alleles affect age of onset and low AAT levels define faster progression rate. Twenty to thirty percent of all dementia patients display AAT and/or We polymorphisms. Effects of AAT may involve inflammation of liver/lung, macrophage activation and iron and lipid metab. AAT, its regulation, and iron metab. represent therapeutic targets and AAT can serve as a biomarker for vulnerability and disease progression.

L3 ANSWER 10 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2006:75151 CAPLUS  
DN 144:169110  
TI Biomarkers and methods for diagnosis of ovarian cancer  
IN Beyer, Wayne F., Jr.; Venetta, Thomas Michael; Groelke, John W.; Blaesius, Rainer H.  
PA Tripath Imaging, Inc., USA  
SO PCT Int. Appl., 127 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006010047	A2	20060126	WO 2005-US24359	20050708
	WO 2006010047	A3	20061221		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,			

NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

US 2006029956 A1 20060209 US 2005-177506 20050708

PRAI US 2004-586856P P 20040709

AB Methods and compns. for identifying ovarian cancer in a patient sample are provided. The methods of the invention comprise detecting overexpression of at least one biomarker in a body sample, wherein the biomarker is selectively overexpressed in ovarian cancer. In preferred embodiments, the body sample is a serum sample. The biomarkers of the invention include any genes or proteins that are selectively overexpressed in ovarian cancer, including, for example, acute phase reactants, lipoproteins, proteins involved in the regulation of the complement system, regulators of apoptosis, proteins that bind Hb, heme, or iron, cytostructural proteins, enzymes that detoxify metabolic byproducts, growth factors, and hormone transporters. In some aspects of the invention, overexpression of a biomarker of interest is detected at the protein level using biomarker-specific antibodies or at the nucleic acid level using nucleic acid hybridization techniques. Kits for practicing the methods of the invention are further provided.

L3 ANSWER 11 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:1178630 CAPLUS

DN 145:485561

TI Novel liver cancer biomarkers, and liver cancer detection method using these biomarkers

IN Uchida, Kazuhiko; Katagiri, Takuya; Sato, Yumi; Fujimoto, Hirotaka

PA MCB, Inc., Japan; Shimazu Corporation

SO Jpn. Kokai Tokkyo Koho, 24pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006308533	A	20061109	JP 2005-134627	20050502
PRAI	JP 2005-134627		20050502		

AB A liver cancer detection method is provided, which uses as a biomarker a protein(s) or its partial peptide(s) whose presence/absence or abundance is different between normal persons and liver cancer patients. The detection is carried out by an immunoassay using an enzyme- or fluorescent-labeled antibody or a mass spectrometry. Also provided is a liver cancer detection biomarker(s) comprising this protein(s) or its peptide(s) which is at least one protein or peptide selected from a group of fibrinogen .alpha. chain consisting of the amino acid sequence expressed with SEQ ID NO 1, fibrinopeptide A like consisting of the amino acid sequence expressed with SEQ ID NO 3, complement C4A consisting of the amino acid sequence expressed with SEQ ID NO 5, inter-.alpha. trypsin inhibitor consisting of the amino acid sequence expressed with SEQ ID NO 7, gelsolin consisting of the amino acid sequence expressed with SEQ ID NO 9, apolipoprotein A1 consisting of the amino acid sequence expressed with SEQ ID NO 11., .alpha.2 macroglobulin consisting of the amino acid sequence expressed with SEQ ID NO 13, and .alpha.1-antitrypsin consisting of the amino acid sequence expressed with SEQ ID NO 15. This group of proteins and peptides further include the fibrinogen .alpha. chain partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 2, the fibrinopeptide A like partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 4, the complement C4A partial peptide

consisting of the amino acid sequence expressed with SEQ ID NO 6, the inter-.alpha. trypsin inhibitor partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 8, the gelsolin partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 10, the apolipoprotein A1 partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 12, the .alpha.2 macroglobulin partial peptide consisting of the amino acid sequence expressed with SEQ ID 14, the .alpha.1-antitrypsin partial peptide consisting of the amino acid sequence expressed with SEQ ID 16, and the inter-.alpha. trypsin inhibitor heavy chain H4 precursor partial peptide consisting of the amino acid sequence expressed with SEQ ID NO 17.

L3 ANSWER 12 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 2006:1091555 CAPLUS  
 DN 145:434454  
 TI External diagnostic system based on protein, part protein/part peptide, or its profile  
 IN Uchida, Kazuhiko; Katagiri, Takuya; Fujimoto, Hirotaka  
 PA Mcbi, Inc., Japan; Shimazu Corporation  
 SO Jpn. Kokai Tokkyo Koho, 33pp.  
 CODEN: JKXXAF  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2006284389	A	20061019	JP 2005-105309	20050331
PRAI	JP 2005-105309		20050331		

AB A method is provided for externally evaluating/identifying with a living body the normal state, the state other than the normal state including disease state (e.g., inflammation, precancerous lesion, cancer, advanced cancer), or the progress degree of disease state. In this method, used as a marker is at least one of an intact particular protein or its part protein/peptide (e.g., proteinase digestion product) in the case where the protein exists as an intact protein with the living body in the normal state while the protein exists as at least one part protein/peptide. The method comprises measuring the kind, abundance and/or abundance ratio of the intact protein, its part protein and/or its part peptide in a biol. sample (e.g., blood) by an immunoassay, a mass spectrometry or else, and thereby, obtaining a protein/part peptide profile.

=> d L3 100-112 bib abs

L3 ANSWER 100 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1995:603982 CAPLUS  
 DN 123:190539  
 TI cDNA sequences for human .alpha.1-antitrypsin  
 IN Davie, Earl W.; Kurachi, Kotoku; Woo, Savio L. C.; Thirumalachary, Chandra  
 PA Washington Research Foundation, USA  
 SO U.S., 15 pp. Cont. of U.S. Ser. No. 979,556, abandoned.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5399684	A	19950321	US 1993-86442	19930702
	US 5736379	A	19980407	US 1995-479545	19950607
	US 6025161	A	20000215	US 1998-9581	19980120
PRAI	US 1982-380310	B1	19820520		
	US 1984-638980	B1	19840207		
	US 1987-22543	B1	19870303		

US 1987-133190	B1	19871215
US 1988-246912	B1	19880916
US 1989-398288	B1	19890822
US 1991-666450	B1	19910311
US 1992-979556	B1	19921118
US 1993-86442	A1	19930702
US 1994-361689	B1	19941212
US 1995-479545	A3	19950607

AB A cDNA encoding human .alpha.1-antitrypsin is cloned and characterized for use in the study of .alpha.1-antitrypsin in disease. .alpha.1-Antitrypsin is an important protease inhibitor present in mammalian blood. Its major physiol. function appears to be the inhibition of neutrophil elastase, a potent protease that hydrolyzes structural proteins. In order to study .alpha.1-antitrypsin deficiency at the mol. level, is is desirable to obtain pure polypeptide. This .alpha.1-antitrypsin polypeptide may be used for the formation of antibodies to numerous determinant sites for detection of variants in the blood. Also, this may be used for introduction into a host having .alpha.1-antitrypsin deficiency. Therefore, cDNA sequences for human .alpha.1-antitrypsin were cloned and may be used for expression of mammalian .alpha.1 -antitrypsin.

L3 ANSWER 101 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:446653 CAPLUS

DN 122:259856

TI Thermoresistant amino acid-substituted analogs of .alpha.1-antitrypsin

IN Yu, Myeong-Hee; Kwon, Ki-Sun; Lee, Kee Nyung; Shin, Hwa Soo

PA Korea Institute of Science and Technology, S. Korea; Korea Green Cross Corp

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426781	A1	19941124	WO 1994-KR48	19940517
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2163081	A1	19941124	CA 1994-2163081	19940517
	CA 2163081	C	20000314		
	EP 701570	A1	19960320	EP 1994-915692	19940517
	EP 701570	B1	20011219		
	R: BE, CH, DE, DK, FR, GB, IT, LI, NL, SE				
	JP 08509865	T	19961022	JP 1994-525260	19940517
	KR 133252	B1	19980414	KR 1994-10902	19940519
	US 5817484	A	19981006	US 1995-553488	19951121
PRAI	KR 1993-8510	A	19930518		
	WO 1994-KR48	W	19940517		

AB Analogs of .alpha.1-antitrypsin (AT) that have amino acid substitutions that improve the resistance of the protein to heat are manufd. by expression of the cloned gene. Increased thermostability indicates an overall resistance to denaturation and may indicate a greater utility of these analogs as therapeutics. A no. of analogs with near normal activity and greater thermostability are prepd. by random or site-directed mutagenesis of a cloned gene and manuf. of the protein in Escherichia coli. Analogs with Phe-51 replaced by Cys showed normal activity and less extensive aggregation at 55.degree. than the wild-type inhibitor.

L3 ANSWER 102 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1993:109675 CAPLUS

DN 118:109675

TI Compositions and methods for inhibiting elastase

IN Miller, Edward J.

PA Uab Research Foundation, USA  
SO PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9218141	A1	19921029	WO 1992-US3207	19920417
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE				
	CA 2108689	A1	19921019	CA 1992-2108689	19920417
	EP 616614	A1	19940928	EP 1992-911506	19920417
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
	JP 06509327	T	19941020	JP 1992-511411	19920417
	US 5668107	A	19970916	US 1995-437029	19950508
PRAI	US 1991-687372	A	19910418		
	WO 1992-US3207	W	19920417		
	US 1992-919992	A3	19920727		

AB A polypeptide moiety, in a suitable carrier, having an identifying no. of amino acids for C-terminal fragment of .alpha.1-antitrypsin (SPAAT), with collagen-, elastin-, and neutrophil elastase-binding activities is developed. The polypeptide can be used for the treatment of pulmonary emphysema and adult respiratory distress syndrome (no data). Isolation, biochem. characterization, protein sequencing, inhibition of enzyme activity, and binding to proteins of SPAAT were given.

L3 ANSWER 103 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1992:537663 CAPLUS  
DN 117:137663  
TI Antitumor molecules which bind to a tumor cell and inhibit a tumor-associated protease  
IN Ballance, David James; Courtney, Michael George  
PA Delta Biotechnology Ltd., UK  
SO Brit. UK Pat. Appl., 57 pp.  
CODEN: BAXXDU  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2246779	A	19920212	GB 1990-17083	19900803
	GB 2246779	B	19940817		
	WO 9202553	A1	19920220	WO 1991-GB1322	19910802
	W: AU, CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AU 9183185	A	19920302	AU 1991-83185	19910802
PRAI	GB 1990-17083	A	19900803		
	WO 1991-GB1322	A	19910802		

AB Mols. comprising a 1st region which binds to a tumor cell and a 2nd region which inhibits a tumor-assocd. protease are prepd. for treating tumors. The 2 regions may be combined by chem. linking them or by expressing a nucleotide sequence encoding the 2 regions as a single polypeptide in a host transformed with the nucleotide sequence. Recombinant prepn. of fusion proteins contg. a methionine residue followed by amino acid residues 1-47 of urokinase-type plasminogen activator (uPA) and then plasminogen activator inhibitor 2 (PAI-2) or .alpha.1-antitrypsin Pittsburgh is described.

L3 ANSWER 104 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1991:672672 CAPLUS  
DN 115:272672  
TI Cloning and expression of human serine proteinase inhibitor cDNA

IN Kalsheker, Noor Ahmed  
 PA 3i Research Exploitation Ltd., UK  
 SO PCT Int. Appl., 30 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9109947	A1	19910711	WO 1990-GB2003	19901221
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	CA 2070399	A1	19910623	CA 1990-2070399	19901221
	EP 506755	A1	19921007	EP 1991-901314	19901221
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	JP 05502376	T	19930428	JP 1991-501703	19901221
	US 5412073	A	19950502	US 1992-859480	19920616
PRAI	GB 1989-29110	A	19891222		
	WO 1990-GB2003	W	19901221		

AB The cDNA for a human serine proteinase inhibitor of mol. wt. 32 +- . 1 kilodaltons (unglycosylated) is cloned and expressed in Escherichia coli. The inhibitor may be useful in treatment of emphysema, arthritis, or septic shock. Human liver cDNA was screened with a DNA probe corresponding to the .alpha.1-antitrypsin gene to identify clone pAT153 contg. the proteinase inhibitor cDNA of the invention.

L3 ANSWER 105 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1992:102250 CAPLUS  
 DN 116:102250

TI .alpha.-1-Antitrypsin peptide and monoclonal antibodies and kit for diagnosis of .alpha.-1-antitrypsin deficiency  
 IN Jeppsson, Jan Olof  
 PA Ferring AB, Swed.  
 SO PCT Int. Appl., 18 pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9108488	A1	19910613	WO 1990-SE768	19901123
	W: AU, CA, FI, NO, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
	AU 9178968	A	19910626	AU 1991-78968	19901123
PRAI	SE 1989-4007	A	19891128		
	WO 1990-SE768	A	19901123		

OS MARPAT 116:102250

AB The decapeptide HX1-Leu-Thr-Ile-Asp-Lys-Lys-Gly-Thr-Gly-Ala-X2Y (X1,X2 = optional coupling-facilitating amino acid; Y = NH2, OH) is used to produce monoclonal antibodies that bind to a single epitope on [Lys342].alpha.1-antitrypsin for in vitro diagnosis of .alpha.1-antitrypsin deficiency. Thus, H-Leu-Thr-Ile-Asp-Lys-Lys-Gly-Thr-Gly-Ala-Cys-OH was conjugated to hemocyanin to produce the above antibodies. Anal. of blood serum by time-resolved fluorescence using the monoclonal antibodies was able to distinguish homozygous PiZ (deficient, ZZ) individuals from heterozygous PiZ (predisposed, MZ) and normal (MM) individuals.

L3 ANSWER 106 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1991:466184 CAPLUS  
 DN 115:66184

TI Fusion proteins containing N-terminal fragments of human serum albumin  
 IN Ballance, David James

PA Delta Biotechnology Ltd., UK  
 SO PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9013653	A1	19901115	WO 1990-GB650	19900426
	W: AU, FI, GB, HU, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	AU 9055646	A	19901129	AU 1990-55646	19900426
	AU 630450	B2	19921029		
	EP 470165	A1	19920212	EP 1990-907285	19900426
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 04506598	T	19921119	JP 1990-506978	19900426
	HU 61049	A2	19921130	HU 1990-4413	19900426
	CA 2015687	A1	19901029	CA 1990-2015687	19900427
	CA 2015687	C	20000829		
	ZA 9003237	A	19910327	ZA 1990-3237	19900427
	IL 94243	A	19951031	IL 1990-94243	19900429
	GB 2246783	A	19920212	GB 1991-19043	19910906
	GB 2246783	B	19921014		
	FI 104255	B	19991215	FI 1991-5073	19911028
	FI 104255	B1	19991215		
	US 5766883	A	19980616	US 1993-153799	19931117
PRAI	GB 1989-9916	A	19890429		
	WO 1990-GB650	A	19900426		
	US 1991-775952	B2	19911029		
	US 1992-847975	B1	19920306		

AB Recombinant fusion proteins comprising an N-terminus derived from human serum albumin (HSA) or an HSA variant fused to a C-terminus which is not HSA, e.g. a human fibronectin fragment, a CD4 fragment, platelet-derived growth factor, transforming growth factor .beta., a von Willebrand's factor fragment, or .alpha.-1-antitrypsin. The HSA N-terminus favors secretion of the fusion proteins from eukaryotic cells. Plasmids encoding HSA 1-387 or HSA 1-195 fused to human fibronectin 585-1578 were prepd. Saccharomyces cerevisiae transformed with these plasmids produced and secreted the fusion proteins.

L3 ANSWER 107 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1990:527705 CAPLUS  
 DN 113:127705  
 TI Regulated expression vectors for yeast  
 IN Burke, Rae L.; Rosenberg, Steven; Shuster, Jeffrey R.; Tekamp-Olson, Patricia; Valenzuela, Pablo D. T.; Barr, Philip J.  
 PA Chiron Corp., USA  
 SO U.S., 32 pp. Cont. of U.S. Ser. No. 760,197.  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4880734	A	19891114	US 1986-868639	19860529
	AT 93894	T	19930915	AT 1989-106868	19840106
	EP 732403	A1	19960918	EP 1996-200286	19840106
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4876197	A	19891024	US 1985-760197	19850729
	US 5089398	A	19920218	US 1989-380783	19890718
	US 5349059	A	19940920	US 1993-42134	19930402
	US 35749	E	19980317	US 1996-710744	19960920
PRAI	US 1983-468589	A2	19830222		



US 1984-609540	A2	19840511
US 1985-760197	A2	19850729
EP 1989-106868	A	19840106
EP 1991-114001	A3	19840106
US 1987-73381	B1	19870713
US 1989-380783	A1	19890718
US 1990-635048	B1	19901228
US 1993-42134	A5	19930402

AB Expression cassettes for use in yeast use regulated or constitutive promoters from yeast genes coupled to the transcription initiation and termination sequences of the yeast glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene are used to attain high levels of expression of heterologous genes. A human superoxide dismutase (SOD) was cloned and expressed in yeast from the GAPDH transcription start site alone or with the GAL4 promoter as regulatable promoter. Expression of the gene in yeast without the GAL promoter resulted in SOD levels of 148 .mu.g SOD/mg (in a medium contg. lactate and glycerol as C sources). Under control of the GAL promoter levels of prodn. in this medium were 0.4 .mu.g SOD/mg protein, if the C source was galactose the yield reached 68 .mu.g SOD/mg protein.

L3 ANSWER 108 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1990:453717 CAPLUS

DN 113:53717

TI Expression of foreign genes in yeast from strongly regulated yeast promoters

IN Burke, Rae Lyn; Rosenberg, Steven; Shuster, Jeffrey R.; Tekamp-Olson, Patricia A.; Valenzuela, Pablo D. T.

PA Chiron Corp., USA

SO U.S., 28 pp. Cont.-in-part of U.S. Ser. No. 468,589, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4876197	A	19891024	US 1985-760197	19850729
	AT 93894	T	19930915	AT 1989-106868	19840106
	EP 732403	A1	19960918	EP 1996-200286	19840106
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4880734	A	19891114	US 1986-868639	19860529
	US 5089398	A	19920218	US 1989-380783	19890718
	US 5349059	A	19940920	US 1993-42134	19930402
	US 35749	E	19980317	US 1996-710744	19960920
PRAI	US 1983-468589	A2	19830222		
	US 1984-609540	A2	19840511		
	EP 1989-106868	A	19840106		
	EP 1991-114001	A3	19840106		
	US 1985-760197	A2	19850729		
	US 1987-73381	B1	19870713		
	US 1989-380783	A1	19890718		
	US 1990-635048	B1	19901228		
	US 1993-42134	A5	19930402		

AB Plasmid constructs contg. regulatory sequences that allow strong, regulated expression of heterologous genes in yeast are described. The transcription initiation region of the glyceraldehyde-3-phosphate dehydrogenase gene and promoters from ADR3, PHO5, or the GAL1-GAL10 intergenic region are used. A chimeric gene encoding a human proinsulin-superoxide dismutase fusion gene was constructed and expressed from a yeast glyceraldehyde-3-phosphate dehydrogenase promoter (GAP) or a chimeric alc. dehydrogenase-GAP promoter. Depending on the promoter used, and the linker between the two domains of the fusion protein, the gene product was up to 10% of total cell protein. The expression of the

proinsulin gene alone from the GAP promoter or as a fusion protein with yeast pyruvate kinase expressed from the pyruvate kinase promoter resulted in proinsulin constituting <0.1% of total protein.

L3 ANSWER 109 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1989:626645 CAPLUS  
 DN 111:226645  
 TI Cloning and expression of human .alpha.-1-antitrypsin gene in yeast  
 IN Kawasaki, Glenn H.; Woodbury, Richard  
 PA Zymogenetics, Inc., USA  
 SO U.S., 13 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4839283	A	19890613	US 1986-946640	19861230
PRAI	US 1986-946640		19861230		

AB CDNA encoding .alpha.-1-antitrypsin (I) of human is cloned and expressed in yeast utilizing a wild-type strain and a hyperprodn. mutant, GK100. Yeast strains N501-B and GK100 were transformed with this plasmid. CDNA encoding human I was cloned. Plasmid HAT4 contg. the leu2 gene, triose phosphate isomerase (TPI) promoter, human I gene, and TPI terminator was constructed from plasmid C1/1. When cultured to a cell d. of .apprx.3 g/L on minimal media with 6% glucose, 2-3 % of the yeast sol. protein produced were I. In GK100 >95% of the cells had plasmid HAT4 after 30 divisions on rich media. Expression of human I using plasmid HAT4 produced .apprx.2-fold more I than those using plasmid CAT1 (without leu2 gene).

L3 ANSWER 110 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
 AN 1986:221366 CAPLUS  
 DN 104:221366  
 TI Active site modified protease .alpha.1-antitrypsin inhibitors  
 IN Barr, Philip J.; Hallewell, Robert A.; Rosenberg, Steven; Brake, Anthony J.  
 PA Chiron Corp., USA  
 SO Eur. Pat. Appl., 37 pp.  
 CODEN: EPXXDW  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 164719	A2	19851218	EP 1985-107126	19850610
	EP 164719	A3	19860806		
	EP 164719	B1	19920506		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4732973	A	19880322	US 1984-620408	19840614
	US 4752576	A	19880621	US 1984-620662	19840614
	AT 75753	T	19920515	AT 1985-107126	19850610
	CA 1341165	C	20010116	CA 1985-483838	19850613
PRAI	US 1984-620408	A	19840614		
	US 1984-620662	A	19840614		
	EP 1985-107126	A	19850610		

AB Novel DNA constructs are described for expression of novel serine peptidase inhibitors in which the amino acid sequence analogous to human .alpha.1-antitrypsin is modified at the active site while maintaining proteinase inhibition. The methiopine at the active site is substd. with an oxidatively stable amino acid, whereas other amino acids may also be changed, added, or deleted. The products have inhibitory activity to human leukocyte elastase comparable to the naturally occurring .alpha.1-antitrypsin. The proteinase inhibitors can be produced in yeast,

particularly *Saccharomyces carlsbergensis*/*S. cerevisiae* hybrid strain  
AB110 (contg. plasmid pCl/1GAPATi9).

L3 ANSWER 111 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1986:473752 CAPLUS  
DN 105:73752  
TI Enhanced yeast transcription employing hybrid promoter region constructs  
IN Rosenberg, Steven; Tekamp-Olson, Patricia  
PA Chiron Corp., USA  
SO Eur. Pat. Appl., 49 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	EP 164556	A2	19851218	EP 1985-105405	19850503
	EP 164556	A3	19870114		
	EP 164556	B1	19940302		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	EP 480480	A2	19920415	EP 1991-121606	19850503
	EP 480480	A3	19920610		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 102250	T	19940315	AT 1985-105405	19850503
	CA 1281671	C	19910319	CA 1985-481401	19850513
	US 5089398	A	19920218	US 1989-380783	19890718
	US 5349059	A	19940920	US 1993-42134	19930402
	US 35749	E	19980317	US 1996-710744	19960920
PRAI	US 1984-609540	A	19840511		
	US 1983-468589	B2	19830222		
	EP 1985-105405	A	19850503		
	US 1987-73381	B1	19870713		
	US 1989-380783	A1	19890718		
	US 1990-635048	B1	19901228		
	US 1993-42134	A5	19930402		

AB Yeast promoters of glycolytic enzyme genes are modified by isolating a fragment that encompasses the RNA polymerase binding site and joining to the 5' end of this fragment a DNA sequence that provides for enhanced inducible or constitutive transcription of a structural gene. These constructs are capable of efficient expression of foreign genes in yeast. Thus, hybrid constructions were prepd. in which the GAL1, GAL10, or PHO5 regulatory regions were linked to the 5' end of a 200-500 bp fragment of the 5'-untranslated region of the yeast glyceraldehyde-3-phosphate dehydrogenase or pyruvate kinase gene. These latter regions contain the ribosome binding sites, extend downstream to at least nucleotide -10, and are proximal to the structural gene that they regulate. Plasmid vectors were constructed that contained the structural genes for hepatitis B surface antigen, .alpha.1-antitrypsin, and superoxide dismutase under the regulation of the above regions. These vectors exhibited improved transcription in yeast.

L3 ANSWER 112 OF 112 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 1986:63387 CAPLUS  
DN 104:63387  
TI .alpha.-1-Antitrypsin mutants, DNA coding for them and therapeutic formulations using these mutants  
IN Insley, Margaret Y.; Kawasaki, Glenn Hitoshi  
PA Zymogenetics, Inc., USA  
SO Eur. Pat. Appl., 31 pp.  
CODEN: EPXXDW  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 155188	A2	19850918	EP 1985-301790	19850314
	EP 155188	A3	19860813		
	EP 155188	B1	19931229		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	US 4711848	A	19871208	US 1985-709382	19850307
	AU 8539819	A	19850919	AU 1985-39819	19850313
	AU 593766	B2	19900222		
	CA 1341219	C	20010501	CA 1985-476337	19850313
	JP 61012289	A	19860120	JP 1985-51553	19850314
	JP 2539781	B2	19961002		
	EP 566158	A1	19931020	EP 1993-107971	19850314
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 99358	T	19940115	AT 1985-301790	19850314
	JP 10113193	A	19980506	JP 1997-275648	19850314
	JP 06105689	A	19940419	JP 1993-115129	19930406
PRAI	JP 2750257	B2	19980513		
	US 1984-589410	A	19840314		
	US 1985-709382	A	19850307		
	EP 1985-301790	A	19850314		
AB	JP 1993-115129	A3	19850314		
	<p>The gene for human .alpha.1-antitrypsin (I) [9041-92-3] is subjected to site-directed mutagenesis and cloning to produce a protein with enhanced stability or antithrombin [9000-94-6] activity. Substitution of methionine-358 in the active site with other amino acids protects the protein from oxidn. Substitution of lysine for glutamic acid-342 produces the Z-allele variant, which is nonimmunogenic when administered to patients homozygous for the Z-allele. [Arg358]I has antithrombin activity and maybe useful as an anticoagulant. For example, site-directed mutagenesis was carried out by annealing an oligonucleotide contg. a desired mutant codon for either position 342 or 358, together with the universal primer of phage M13, to single-stranded recombinant M13 DNA contg. the wild-type I gene. Active phage was produced by oligonucleotide extension, and ligation, and transfection into competent Escherichia coli K12. The mutant I coding region was removed by digestion with BamHI and PstI and inserted into an expression vector, e.g. M13 mp 10.</p>				

Day : Friday  
Date: 2/23/2007


**PALM INTRANET**

Time: 13:45:03

**Inventor Name Search Result**

Your Search was:

Last Name = FERKOL

First Name = THOMAS

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<u>09114475</u>	<u>6077835</u>	150	07/13/1998	NUCLEIC ACID TO CELLS DELIVERY OF COMPACTED	FERKOL JR., THOMAS W.
<u>08957333</u>	<u>6072041</u>	150	10/24/1997	FUSION PROTEINS FOR PROTEIN DELIVERY	FERKOL, THOMAS
<u>09559393</u>	<u>6287817</u>	150	04/26/2000	Fusion proteins for protein delivery	FERKOL, THOMAS
<u>60145970</u>	Not Issued	159	07/29/1999	ENHANCED DELIVERY VIA SERPIN ENZYME COMPLEX RECEPTOR	FERKOL, THOMAS
<u>10703206</u>	Not Issued	161	11/07/2003	Enhanced delivery via serpin enzyme complex receptor	FERKOL, THOMAS W.
<u>11455791</u>	Not Issued	30	06/20/2006	Enhanced delivery via serpin enzyme complex receptor	FERKOL, THOMAS W.
<u>08655705</u>	<u>5972900</u>	150	06/03/1996	DELIVERY OF NUCLEIC ACID TO CELLS	FERKOL, THOMAS W.
<u>08656906</u>	<u>5972901</u>	150	06/03/1996	SERPIN ENZYME COMPLEX RECEPTOR - MEDIATED GENE TRANSFER	FERKOL, THOMAS W.
<u>08716415</u>	<u>5877302</u>	150	02/12/1997	COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS	FERKOL, THOMAS W.
<u>08721094</u>	<u>5844107</u>	150	09/27/1996	COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS	FERKOL, THOMAS W.
<u>09054453</u>	<u>6008336</u>	150	04/03/1998	COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS	FERKOL, THOMAS W.
<u>09217847</u>	<u>6200801</u>	150	12/21/1998	SERPIN ENZYME COMPLEX RECEPTOR- MEDIATED GENE TRANSFER	FERKOL, THOMAS W.
<u>09264032</u>	<u>6261787</u>	150	03/08/1999	BIFUNCTIONAL MOLECULES FOR DELIVERY OF	FERKOL, THOMAS W.

				THERAPEUTICS	
<u>08216534</u>	Not Issued	161	03/23/1994	COMPACTED NUCLEIC ACIDS AND THEIR DELIVERY TO CELLS	FERKOL,, THOMAS W.

Inventor Search Completed: No Records to Display.

**Search Another: Inventor**

Last Name	First Name	
<input type="text" value="Ferkol"/>	<input type="text" value="Thomas"/>	<input type="button" value="Search"/>

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Day : Friday  
Date: 2/23/2007


**PALM INTRANET**

Time: 13:47:15

**Inventor Name Search Result**

Your Search was:

Last Name = DAVIS

First Name = PAMELA

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<a href="#">08957333</a>	<a href="#">6072041</a>	150	10/24/1997	FUSION PROTEINS FOR PROTEIN DELIVERY	DAVIS, PAMELA
<a href="#">10290402</a>	<a href="#">6810883</a>	150	11/08/2002	ELECTRICALLY HEATED CIGARETTE SMOKING SYSTEM WITH INTERNAL MANIFOLDING FOR PUFF DETECTION	DAVIS, PAMELA
<a href="#">10837572</a>	Not Issued	30	05/04/2004	Electrically heated cigarette smoking system with internal manifolding for puff detection	DAVIS, PAMELA
<a href="#">60003029</a>	Not Issued	159	08/31/1995	DIET TO TREAT CYSTIC FIBROSIS	DAVIS, PAMELA
<a href="#">06711551</a>	Not Issued	166	03/14/1985	OSCILATING PRESSURE DEVICE FOR DYNAMIC CALIBRATION OF PRESSURE TRANSDUCERS	DAVIS, PAMELA A.
<a href="#">06890983</a>	<a href="#">4698997</a>	150	07/30/1986	OSCILLATION PRESSURE DEVICE FOR DYNAMIC CALIBRATION OF PRESSURE TRANSDUCERS	DAVIS, PAMELA A.
<a href="#">09512260</a>	<a href="#">6770739</a>	150	02/24/2000	ENHANCERS OF CFTR CHLORIDE CHANNEL FUNCTION	DAVIS, PAMELA B.
<a href="#">09559393</a>	<a href="#">6287817</a>	150	04/26/2000	Fusion proteins for protein delivery	DAVIS, PAMELA B.
<a href="#">09914213</a>	Not Issued	161	12/17/2001	Enhancers of cftr chloride channel function	DAVIS, PAMELA B.
<a href="#">10703206</a>	Not Issued	161	11/07/2003	Enhanced delivery via serpin enzyme complex receptor	DAVIS, PAMELA B.
<a href="#">10743381</a>	Not Issued	161	12/23/2003	Enhancers of CFTR chloride channel function	DAVIS, PAMELA B.
<a href="#">11455791</a>	Not Issued	30	06/20/2006	Enhanced delivery via serpin enzyme complex receptor	DAVIS, PAMELA B.

<a href="#">60687511</a>	Not Issued	159	06/03/2005	Methods and compositions for treating inflammation	DAVIS, PAMELA B.
<a href="#">08655705</a>	<a href="#">5972900</a>	150	06/03/1996	DELIVERY OF NUCLEIC ACID TO CELLS	DAVIS, PAMELA B.
<a href="#">08656906</a>	<a href="#">5972901</a>	150	06/03/1996	SERPIN ENZYME COMPLEX RECEPTOR - MEDIATED GENE TRANSFER	DAVIS, PAMELA B.
<a href="#">09217847</a>	<a href="#">6200801</a>	150	12/21/1998	SERPIN ENZYME COMPLEX RECEPTOR- MEDIATED GENE TRANSFER	DAVIS, PAMELA B.
<a href="#">09264032</a>	<a href="#">6261787</a>	150	03/08/1999	BIFUNCTIONAL MOLECULES FOR DELIVERY OF THERAPEUTICS	DAVIS, PAMELA B.
<a href="#">60121495</a>	Not Issued	159	02/24/1999	ENHANCERS OF CFTR CHLORIDE CHANNEL FUNCTION	DAVIS, PAMELA B.
<a href="#">60145970</a>	Not Issued	159	07/29/1999	ENHANCED DELIVERY VIA SERPIN ENZYME COMPLEX RECEPTOR	DAVIS, PAMELA B.
<a href="#">10252012</a>	Not Issued	161	09/23/2002	Q4N2NEG2 enhances CFTR activity	DAVIS, PAMELA BOWES
<a href="#">60323724</a>	Not Issued	159	09/21/2001	Q4N2NEG2 enhances CFTR activity	DAVIS, PAMELA BOWES
<a href="#">29127865</a>	Not Issued	160	08/14/2000	Hawaiian magnetic cake decorating spin game	DAVIS, PAMELA CAPPS
<a href="#">60881095</a>	Not Issued	20	01/19/2007	Under the dryer protector	DAVIS, PAMELA LEORA
<a href="#">10062778</a>	Not Issued	161	02/05/2002	Sleeve for beverage containers	DAVIS, PAMELA SUE
<a href="#">09356731</a>	<a href="#">6058943</a>	150	07/18/1999	FORMULATION AND METHOD FOR SMOOTHING AND WAVING MULTI-TEXTURED HAIR	DAVISHARRIS, PAMELA

Inventor Search Completed: No Records to Display.

Search Another: Inventor	Last Name	First Name	<input type="button" value="Search"/>
	<input type="text" value="Davis"/>	<input type="text" value="Pamela"/>	

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



Day : Friday  
Date: 2/23/2007

Time: 13:48:11

 **PALM INTRANET**

## Inventor Name Search Result

Your Search was:

Last Name = ZIADY

First Name = ASSEM

Application#	Patent#	Status	Date Filed	Title	Inventor Name
<a href="#">10477211</a>	Not Issued	160	01/01/0001	Enhanced delivery via serpin enzyme complex receptor	ZIADY, ASSEM
<a href="#">10703206</a>	Not Issued	161	11/07/2003	Enhanced delivery via serpin enzyme complex receptor	ZIADY, ASSEM
<a href="#">11455791</a>	Not Issued	30	06/20/2006	Enhanced delivery via serpin enzyme complex receptor	ZIADY, ASSEM
<a href="#">60145970</a>	Not Issued	159	07/29/1999	ENHANCED DELIVERY VIA SERPIN ENZYME COMPLEX RECEPTOR	ZIADY, ASSEM
<a href="#">09217847</a>	<a href="#">6200801</a>	150	12/21/1998	SERPIN ENZYME COMPLEX RECEPTOR- MEDIATED GENE TRANSFER	ZIADY, ASSEM-GALAL

Inventor Search Completed: No Records to Display.

Search Another: Inventor

Last Name	First Name
<input type="text" value="Ziady"/>	<input type="text" value="Assem"/>
<input type="button" value="Search"/>	

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)